Predict your next investment

Venture Capital
westlakebio.com

See what CB Insights has to offer

Investments

11

Funds

3

About Westlake Village BioPartners

Westlake Village BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs that have the potential to bring transformative therapies and technologies to patients.

Westlake Village BioPartners Headquarter Location

3075 Townsgate Road Suite 140

Westlake Village, California, 91361,

United States

805-465-9588

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Westlake Village BioPartners News

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases

Nov 17, 2021

ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases Series B led by AyurMaya, an affiliated fund of Matrix Capital Management, Surveyor Capital (a Citadel company), and Westlake Village BioPartners Currently enrolling izokibep in pivotal trial in uveitis and Phase 2b trial in axial spondyloarthritis; activities underway for Phase 2b trial in hidradenitis suppurativa LOS ANGELES, November 16, 2021-- ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today announced the completion of a $250 million Series B financing led by AyurMaya, an affiliated fund of Matrix Capital Management ("Matrix"), Surveyor Capital (a Citadel company), and Westlake Village BioPartners ("Westlake"). Additional new investors include Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, RTW Investments, LP, Samsara BioCapital, Tybourne Capital Management, and venBio Partners. ACELYRIN also announced it has entered into an agreement with Affibody AB to develop and commercialize izokibep, a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies and provide potential for meaningfully differentiated efficacy in several autoimmune diseases. The exquisite potency and small size of izokibep enables enhanced tissue penetration and high exposures in a single subcutaneous injection; exposures monoclonal antibodies require IV administration to approach. The proceeds from the Series B financing will be used to fund licensing and acquisition of additional programs, with a focus in immunology, and accelerate the development of izokibep. "We are pleased this syndicate of blue-chip investors has committed to ACELYRIN and our mission to identify, license, and develop transformative therapies for patients with serious diseases and unmet needs," said Shao-Lee Lin, MD, PhD, co-founder and chief executive officer (CEO) of ACELYRIN. "This financing catalyzes our ability to rapidly advance the late-phase development of izokibep and demonstrate its potential for differentiation within the class of IL-17 inhibitors, both by unlocking new indications as well as achieving differentiated efficacy in existing blockbuster indications, where significant unmet needs persist. The financing also catapults our ability to proactively build the company and aggressively pursue the expansion of our portfolio to meaningfully improve patients' lives." "As the lead Series A investor, we want to thank and welcome this impressive group of Series B investors in joining us to support ACELYRIN. This is a management team we know well and have every confidence will achieve its goal of building a fully integrated biopharma company with a robust pipeline and broad research, development, and commercialization capabilities," said Westlake's co-founding managing director and ACELYRIN Board member, Sean Harper, MD. "ACELYRIN's founders have a long track record of bringing life-changing medicines to patients with immunologic diseases. These medicines are amongst some of the most successful drugs, reflecting the team's ability to identify significant unmet medical need and bring innovative solutions to meet those needs," said Alan Colowick, MD, managing director, Matrix. "We believe izokibep is the first of many assets that the company will develop to transform patients' lives, and we are excited to be a partner in that journey along with the other investors and management team." The Company is currently enrolling izokibep in a pivotal trial for the treatment of uveitis, a vision-threatening form of inflammation inside the eye, and a Phase 2b trial for the treatment of axial spondyloarthritis (AS), a chronic form of arthritis that primarily affects the spine and enthesites, specialized tissue that connects ligaments and tendons to bone. In addition, ACELYRIN plans to initiate a Phase 2b trial for hidradenitis suppurativa (HS), a devastating, chronic inflammatory disease of the exocrine sweat glands characterized by painful, malodorous nodules and abscesses in the axilla, groin, and gluteal areas that can become scarred and disfiguring. "As the innovators of izokibep, we're honored to work with ACELYRIN to unlock this molecule's potential and address promising new indications and solve unmet needs," said David Bejker, CEO of Affibody AB. "In addition, we look forward to working with the ACELYRIN team to select additional targets and build new programs, in parallel with the development of izokibep." Under the terms of the transaction with Affibody AB, ACELYRIN has obtained worldwide rights to izokibep except development and commercialization by Inmagene Biopharmaceuticals Co., Ltd. in selected Asian countries, including China, Hong Kong, South Korea, and Taiwan, and excluding Japan, and commercialization by Affibody in the Nordic Countries. The agreement with Affibody AB also includes an option for ACELYRIN to license additional molecules developed by Affibody AB. The Company is adding Richard Gaster, MD, of venBio Partners and Dr. Colowick to its board of directors. About Izokibep Izokibep is a unique, antibody mimetic, interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous injection that monoclonal antibodies require IV administration to achieve. In addition, the molecule's small size—about a tenth the size of a monoclonal antibody—also enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies. More than 300 patients have been exposed to izokibep to date, many for up to three years. These data confirm the safety profile of izokibep and support the strategy of fully evaluating IL-17A inhibition in pursuit of transformative efficacy across many disease states. About ACELYRIN ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. The company was founded in late 2020. For more information, visit www.acelyrin.com.

Westlake Village BioPartners Investments

11 Investments

Westlake Village BioPartners has made 11 investments. Their latest investment was in Recludix Pharma as part of their Series A on November 11, 2021.

CBI Logo

Westlake Village BioPartners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2021

Series A

Recludix Pharma

$60M

Yes

3

11/16/2021

Series B

ACELYRIN

$250M

No

5

9/29/2021

Series B

Expansion Therapeutics

$80M

Yes

4

4/29/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2021

Series F

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/17/2021

11/16/2021

9/29/2021

4/29/2021

1/5/2021

Round

Series A

Series B

Series B

Series A

Series F

Company

Recludix Pharma

ACELYRIN

Expansion Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$60M

$250M

$80M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

5

4

10

10

Westlake Village BioPartners Fund History

3 Fund Histories

Westlake Village BioPartners has 3 funds, including Westlake BioPartners Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/15/2020

Westlake BioPartners Fund II

$430M

2

12/15/2020

Westlake BioPartners Opportunity Fund I

Subscribe to see more

$99M

10

9/4/2018

Westlake BioPartners Fund I

Subscribe to see more

$99M

10

Closing Date

12/15/2020

12/15/2020

9/4/2018

Fund

Westlake BioPartners Fund II

Westlake BioPartners Opportunity Fund I

Westlake BioPartners Fund I

Fund Type

Subscribe to see more

Subscribe to see more

Status

Amount

$430M

$99M

$99M

Sources

2

10

10

Westlake Village BioPartners Team

2 Team Members

Westlake Village BioPartners has 2 team members, including current Chief Operating Officer, Scott A Ryles.

Name

Work History

Title

Status

Scott A Ryles

Chief Operating Officer

Current

Sean Harper

Managing Partner

Current

Name

Scott A Ryles

Sean Harper

Work History

Title

Chief Operating Officer

Managing Partner

Status

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.